Clinical Cancer Research, Vol 2, Issue 8 1405-1409, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden

R Mouawad, A Benhammouda, O Rixe, EC Antoine, C Borel, M Weil, D Khayat and C Soubrane
Laboratory of the Medical Oncology Department, Salpetriere Hospital, 47 boulevard de l'Hopital, 75013 Paris, France.

The involvement of interleukin (IL-) 6 in malignant disease has been investigated in a variety of different malignancies. To evaluate whether serum IL-6 is a useful disease marker in metastatic malignant melanoma (MMM), we studied the time course of endogenous IL-6 secretion in 41 patients treated with cisplatinum, IL-2, and IFN-alpha. Furthermore, the relationship of endogenous IL-6 concentrations to the tumor burden and/or the clinical response was also evaluated. The baseline serum IL-6 levels were significantly higher in patients with MMM than in the control group (P = 0.002). When tumor burden was taken into consideration, we found that IL-6 levels were higher in patients with high tumor burden than in patients with low tumor burden. During treatment in the whole patient population, a higher serum IL-6 level was observed in nonresponding as compared to responding patients at days 7 (P = 0.0005), 21 (P = 0.002), and 35 (P = 0.009). The follow-up of serum IL-6 in patients with MMM according to the tumor burden and clinical response demonstrated that: (a) IL-6 levels were significantly higher at days 7 and 21 in patients with high tumor burden as compared to those with low tumor burden; and (b) IL-6 levels remain significantly higher in nonresponding patients as compared to responding patients regardless of the tumor burden. From these results, we can conclude that endogenous IL-6 may play a role in the failure of IL-2 therapy in such patients, since the very early IL-6 increase is correlated with the tumor mass and nonresponse to biochemotherapy. Therefore, it seems that the early detection of endogenous IL-6 may represent valuable information for monitoring the response to biochemotherapy in patients with MMM.

This article has been cited by other articles:

				P. E. Di Cesare, E. Chang, C. F. Preston, and C.-j. Liu Serum Interleukin-6 as a Marker of Periprosthetic Infection Following Total Hip and Knee Arthroplasty J. Bone Joint Surg. Am., September 1, 2005; 87(9): 1921 - 1927. [Abstract] [Full Text] [PDF]

				V. von Felbert, F. Cordoba, J. Weissenberger, C. Vallan, M. Kato, I. Nakashima, L. R. Braathen, and J. Weis Interleukin-6 Gene Ablation in a Transgenic Mouse Model of Malignant Skin Melanoma Am. J. Pathol., March 1, 2005; 166(3): 831 - 841. [Abstract] [Full Text] [PDF]

				M. Trikha, R. Corringham, B. Klein, and J.-F. Rossi Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence Clin. Cancer Res., October 15, 2003; 9(13): 4653 - 4665. [Abstract] [Full Text] [PDF]

				C. Belluco, F. Olivieri, M. Bonafe, S. Giovagnetti, E. Mammano, R. Scalerta, A. Ambrosi, C. Franceschi, D. Nitti, and M. Lise -174G>C Polymorphism of Interleukin 6 Gene Promoter Affects Interleukin 6 Serum Level in Patients with Colorectal Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2173 - 2176. [Abstract] [Full Text] [PDF]

				S. Metzger, T. Hassin, V. Barash, O. Pappo, and T. Chajek-Shaul Reduced body fat and increased hepatic lipid synthesis in mice bearing interleukin-6-secreting tumor Am J Physiol Endocrinol Metab, November 1, 2001; 281(5): E957 - E965. [Abstract] [Full Text] [PDF]